title: Protective effects of ITF 296 in the isolated rabbit heart subjected to global ischemia.
abstract: The anti-ischemic action of ITF 296 was evaluated in isovolumic, electrically driven rabbit heart preparations subjected to temporary ischemia and reperfusion. Reduction of perfusion rate from 20 to 0.2 ml/min produced a sharp decrease of peak systolic pressure, left ventricular (LV)-developed pressure, and LV dP/dt, which culminated in complete ventricular arrest within 3-4 min. Thereafter, LV end-diastolic pressure (LVEDP) progressively increased, suggesting a severe ischemic episode. Reperfusion with 20 ml Krebs solution/min after 40 min of low-flow perfusion produced only minimal recovery from the rhythm disturbances associated with cardiac mechanical activity. During reperfusion, loss of myocardial elasticity was associated with a significant increase in coronary vascular resistance, as indicated by the augmentation of coronary perfusion pressure. Injection of ITF 296 (0.3-10 microM) into the perfusion system dose-dependently inhibited the increase in LVEDP that took place during ischemia and progressively improved the recovery of a regular rhythm in the isolated heart. Isosorbide dinitrate (ISDN) at a concentration of 10 microM exerted a protective action on the myocardium similar to that obtained with ITF 296 (3 microM). Treatment with ITF 296 (1 and 10 microM) resulted in a dose-dependent increase in the rate of 6-keto-PGF1 alpha biosynthesis during both the ischemia and the reperfusion period (+157% over basal values). Similar results were obtained when hearts were pretreated with ISDN (10 microM). Infusion of a buffer containing NG-monomethyl-L-arginine (L-NMMA; NO synthase inhibitor at 10 microM) just before reduction of flow, markedly exacerbated the effects of ischemia and reperfusion on the myocardium and increased coronary perfusion pressure. The effects of L-NMMA were clearly antagonized by ITF 296 (10 microM) or L-arginine (100 microM). Mechanical activity and sinus rhythm during reperfusion were rapidly and completely restored, and coronary resistance values were close to the preischemic values. As with ISDN, ITF 296 significantly increased the rate of synthesis of 6-keto-PGF1 alpha both under basal conditions and during reperfusion.
authors.affiliation: Department of Pharmacology, Chemotherapy and Medical Toxicology, University of Milano, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Rossoni
authors.forename: F
authors.initials: F
authors.lastname: Berti
authors.forename: M
authors.initials: M
authors.lastname: Bernareggi
authors.forename: L
authors.initials: L
authors.lastname: Villa
authors.forename: S
authors.initials: S
authors.lastname: Agozzino
authors.forename: R
authors.initials: R
authors.lastname: Cereda
authors.forename: P
authors.initials: P
authors.lastname: Giuliani
authors.forename: J
authors.initials: J
authors.lastname: Mizrahi
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000818:Animals; D048588:Benzoxazines; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D011464:Epoprostenol / Q000378:metabolism; D066298:In Vitro Techniques; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D017202:Myocardial Ischemia / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D015428:Myocardial Reperfusion Injury / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D009566:Nitrates / Q000627:therapeutic use*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D010078:Oxazines / Q000627:therapeutic use*; D011817:Rabbits; D014665:Vasodilator Agents / Q000627:therapeutic use*; D019323:omega-N-Methylarginine / Q000627:therapeutic use
chemical_list: D048588:Benzoxazines; D004791:Enzyme Inhibitors; D009566:Nitrates; D010078:Oxazines; D014665:Vasodilator Agents; D019323:omega-N-Methylarginine; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D019001:Nitric Oxide Synthase; C091726:sinitrodil